Vaccines - Timor-Leste

Timor-Leste

The Vaccines market in Timor-Leste is projected to reach US$6.73m in revenue by 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of -14.70%, resulting in a market volume of US$3.04m by 2029.
In global comparison, United States is anticipated to generate the highest revenue of US$29,120.00m in 2024.
In Timor-Leste, there is a growing demand for vaccines due to the country's commitment to improving public health.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Timor-Leste has been increasing steadily in recent years.

Customer preferences: Timor-Leste has a young population and a high birth rate, which has contributed to an increase in demand for vaccines. The country has a national immunization program that aims to provide free vaccines to all children under the age of five. However, due to limited resources and infrastructure challenges, the coverage of the program is not yet universal.

Trends in the market: The vaccines market in Timor-Leste is still in its early stages of development. The market is dominated by a few multinational companies that produce and distribute vaccines globally. The demand for vaccines in Timor-Leste is expected to continue to grow as the government expands its immunization program and the population becomes more aware of the importance of vaccination.

Local special circumstances: Timor-Leste is a small, developing country with limited resources and infrastructure challenges. The country has a high poverty rate, which makes it difficult for many families to afford healthcare services, including vaccines. The government has been working to address these challenges by investing in healthcare infrastructure and expanding its immunization program.

Underlying macroeconomic factors: The economy of Timor-Leste is heavily dependent on oil and gas exports, which account for the majority of government revenue. The country has a relatively low GDP per capita, which limits the ability of many families to afford healthcare services, including vaccines. The government has been working to diversify the economy and reduce its dependence on oil and gas exports, which could help to improve the overall economic situation in the country and increase access to healthcare services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.